Obesity and Clinical Outcomes in COVID-19 Patients Without Comorbidities, a Analysis from ORCHID Trial

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Aug 15

PMID 35966085

Authors

Peng Yu

Ziqi Tan

Zhangwang Li

Yi Xu

Jing Zhang

Panpan Xia

Xiaoyi Tang

Jianyong Ma

Minxuan Xu

Xiao Liu

Yunfeng Shen

Affiliations

Soon will be listed here.

Abstract

Objective: Large body of studies described individuals with obesity experiencing a worse prognosis in COVID-19. However, the effects of obesity on the prognosis of COVID-19 in patients without comorbidities have not been studied. Therefore, the current study aimed to provide evidence of the relationship between obesity and clinical outcomes in COVID-19 patients without comorbidities.

Methods: A total of 116 hospitalized COVID-19 patients without comorbidities from the ORCHID study (Patients with COVID-19 from the Outcomes Related to COVID-19 Treated with Hydroxychloroquine among Inpatients with Symptomatic Disease) were included. Obesity is defined as a BMI of ≥30 kg/m. A Cox regression analysis was used to estimate the hazard ratio () for discharge and death after 28 days.

Results: The percentage of obesity in COVID-19 patients without comorbidities was 54.3% (63/116). Discharge at 28 days occurred in 56/63 (84.2%) obese and 51/53 (92.2%) non-obese COVID-19 patients without comorbidities. Four (3.4%) COVID-19 patients without any comorbidities died within 28 days, among whom 2/63 (3.2%) were obese and 2/53 (3.8%) were non-obese. Multivariate Cox regression analyses showed that obesity was independently associated with a decreased rate of 28-day discharge (adjusted : 0.55, 95% : 0.35-0.83) but was not significantly associated with 28-day death (adjusted : 0.94, 95% : 0.18-7.06) in COVID-19 patients without any comorbidities.

Conclusions: Obesity was independently linked to prolonged hospital length of stay in COVID-19 without any comorbidity. Larger prospective trials are required to assess the role of obesity in COVID-19 related deaths.

Citing Articles

Repurposing of Chemotherapeutics to Combat COVID-19.

Nandi S, Nayak B, Khede M, Saxena A Curr Top Med Chem. 2022; 22(32):2660-2694.

PMID: 36453483 DOI: 10.2174/1568026623666221130142517.

References

Ryan P, Caplice N . Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019?. Obesity (Silver Spring). 2020; 28(7):1191-1194. PMC: 7264526. DOI: 10.1002/oby.22843. View

Self W, Semler M, Leither L, Casey J, Angus D, Brower R . Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(21):2165-2176. PMC: 7653542. DOI: 10.1001/jama.2020.22240. View

Ebinger J, Achamallah N, Ji H, Claggett B, Sun N, Botting P . Pre-existing traits associated with Covid-19 illness severity. PLoS One. 2020; 15(7):e0236240. PMC: 7377468. DOI: 10.1371/journal.pone.0236240. View

Williamson E, Walker A, Bhaskaran K, Bacon S, Bates C, Morton C . Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821):430-436. PMC: 7611074. DOI: 10.1038/s41586-020-2521-4. View

Gao M, Piernas C, Astbury N, Hippisley-Cox J, ORahilly S, Aveyard P . Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021; 9(6):350-359. PMC: 8081400. DOI: 10.1016/S2213-8587(21)00089-9. View

Siurana J, Ventura P, Yeste D, Riaza-Martin L, Arciniegas L, Clemente M . Myocardial Geometry and Dysfunction in Morbidly Obese Adolescents (BMI 35-40 kg/m). Am J Cardiol. 2021; 157:128-134. DOI: 10.1016/j.amjcard.2021.07.026. View

Huang Y, Lu Y, Huang Y, Wang M, Ling W, Sui Y . Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism. 2020; 113:154378. PMC: 7521361. DOI: 10.1016/j.metabol.2020.154378. View

Townsend M, Kyle T, Stanford F . Outcomes of COVID-19: disparities in obesity and by ethnicity/race. Int J Obes (Lond). 2020; 44(9):1807-1809. PMC: 7347050. DOI: 10.1038/s41366-020-0635-2. View

Ashburn D, DeAntonio A, Reed M . Pulmonary system and obesity. Crit Care Clin. 2010; 26(4):597-602. DOI: 10.1016/j.ccc.2010.06.008. View

10.

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

11.

Levine M, Ensom M . Post hoc power analysis: an idea whose time has passed?. Pharmacotherapy. 2001; 21(4):405-9. DOI: 10.1592/phco.21.5.405.34503. View

12.

Flegal K, Graubard B, Williamson D, Gail M . Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005; 293(15):1861-7. DOI: 10.1001/jama.293.15.1861. View

13.

Suleyman G, Fadel R, Malette K, Hammond C, Abdulla H, Entz A . Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw Open. 2020; 3(6):e2012270. PMC: 7298606. DOI: 10.1001/jamanetworkopen.2020.12270. View

14.

Tripathi S, Christison A, Levy E, McGravery J, Tekin A, Bolliger D . The Impact of Obesity on Disease Severity and Outcomes Among Hospitalized Children With COVID-19. Hosp Pediatr. 2021; 11(11):e297-e316. DOI: 10.1542/hpeds.2021-006087. View

15.

Zhou Y, Chi J, Lv W, Wang Y . Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2020; 37(2):e3377. PMC: 7361201. DOI: 10.1002/dmrr.3377. View

16.

Stefan N, Birkenfeld A, Schulze M, Ludwig D . Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020; 16(7):341-342. PMC: 7187148. DOI: 10.1038/s41574-020-0364-6. View

17.

Stefan N, Sippel K, Heni M, Fritsche A, Wagner R, Jakob C . Obesity and Impaired Metabolic Health Increase Risk of COVID-19-Related Mortality in Young and Middle-Aged Adults to the Level Observed in Older People: The LEOSS Registry. Front Med (Lausanne). 2022; 9:875430. PMC: 9131026. DOI: 10.3389/fmed.2022.875430. View

18.

Rothman K . BMI-related errors in the measurement of obesity. Int J Obes (Lond). 2008; 32 Suppl 3:S56-9. DOI: 10.1038/ijo.2008.87. View

19.

Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z . Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020; 145(6). DOI: 10.1542/peds.2020-0702. View

20.

Stefan N . Metabolic disorders, COVID-19 and vaccine-breakthrough infections. Nat Rev Endocrinol. 2021; 18(2):75-76. PMC: 8647056. DOI: 10.1038/s41574-021-00608-9. View